HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Therapeutic potential of a new phosphodiesterase inhibitor in acute lung injury.

Abstract
The effects of LASSBio596, a phosphodiesterase type-4 and -5 inhibitor, were tested in Escherichia coli lipopolysaccharide (LPS)-induced acute lung injury. Twenty-four BALB/c mice were randomly divided into four groups. In the control group, saline (0.05 mL) was injected intratracheally (i.t.). The LPS group received LPS (10 microg i.t., 0.05 mL). In the LASSBio596 groups, LASSBio596 (10 mg x kg(-1), 0.2 mL) was injected intraperitoneally 1 h before or 6 h after LPS administration. After 24 h, in vivo (lung resistive and viscoelastic pressures, and static and dynamic elastances) and in vitro (tissue resistance, elastance and hysteresivity) pulmonary mechanics, lung morphometry and collagenous fibre content were computed. Neutrophils and tumour necrosis factor (TNF)-alpha levels were evaluated in the bronchoalveolar lavage fluid. LASSBio596 prevented the changes in lung mechanics, and inhibited neutrophilic recruitment, TNF-alpha release, bronchoconstriction, alveolar collapse and the increment of collagen fibre content induced by LPS, independently of the moment of injection. In conclusion, LASSBio596 modulated the lung inflammatory process and had the potential to block fibroproliferation. Thus, agents that inhibit phosphodiesterase 4 and 5 simultaneously may be a useful adjunct therapy for acute lung injury.
AuthorsP R M Rocco, D P Momesso, R C Figueira, H C Ferreira, R A Cadete, A Légora-Machado, V L G Koatz, L M Lima, E J Barreiro, W A Zin
JournalThe European respiratory journal (Eur Respir J) Vol. 22 Issue 1 Pg. 20-7 (Jul 2003) ISSN: 0903-1936 [Print] England
PMID12882446 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Lipopolysaccharides
  • Phosphodiesterase Inhibitors
  • Piperazines
  • Purines
  • Sulfones
  • Tumor Necrosis Factor-alpha
  • Thalidomide
  • Sildenafil Citrate
Topics
  • Analysis of Variance
  • Animals
  • Bronchoalveolar Lavage Fluid (chemistry)
  • Lipopolysaccharides
  • Mice
  • Mice, Inbred BALB C
  • Neutrophils (metabolism)
  • Phosphodiesterase Inhibitors (pharmacology)
  • Piperazines (chemistry)
  • Purines
  • Respiratory Distress Syndrome (pathology, prevention & control)
  • Respiratory Function Tests
  • Respiratory Mechanics
  • Sildenafil Citrate
  • Statistics, Nonparametric
  • Sulfones
  • Thalidomide (analogs & derivatives, chemistry, pharmacology)
  • Tumor Necrosis Factor-alpha (analysis)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: